Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer

Molecular Pharmaceutics

Volumn 13, Issue 6, 2016, Pages 2070-2083

  Schumann, Canan ^a   Chan, Stephanie ^a   Khalimonchuk, Oleh ^b,c   Khal, Shannon ^a   Moskal, Vitaliya ^a   Shah, Vidhi ^a   Alani, Adam W G ^a   Taratula, Olena ^a   Taratula, Oleh ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cisplatin; dendrimer; DJ 1; LHRH; nanomedicine; ovarian cancer; siRNA

Indexed keywords

DENDRIMER; DJ 1 PROTEIN; MESSENGER RNA; PLATINUM; PROTEIN BAX; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CASPASE; GONADORELIN RECEPTOR; PLATINUM COMPLEX; PROTEIN DEGLYCASE DJ-1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; OVARY CANCER; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; STATIC ELECTRICITY; STEADY STATE; TREATMENT RESPONSE; TUMOR INVASION; UPREGULATION; ZETA POTENTIAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; NANOMEDICINE; OVARIAN NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NANOMEDICINE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROTEIN DEGLYCASE DJ-1; REACTIVE OXYGEN SPECIES; RECEPTORS, LHRH; RNA, SMALL INTERFERING;

EID: 84973616519     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00205     Document Type: Article

References (70)

1. McCorkle, R.; Pasacreta, J.; Tang, S. T. The Silent Killer: Psychological Issues in Ovarian Cancer Holist. Nurs. Pract. 2003, 17, 300-308 10.1097/00004650-200311000-00005
2. Cancer Facts and Figures; American Cancer Society: 2016. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/.
3. Bristow, R. E.; Tomacruz, R. S.; Armstrong, D. K.; Trimble, E. L.; Montz, F. J. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis J. Clin. Oncol. 2002, 20, 1248-1259 10.1200/JCO.20.5.1248
4. Lim, M. C.; Kang, S.; Lee, K. S.; Han, S. S.; Park, S. J.; Seo, S. S.; Park, S. Y. The Clinical Significance of Hepatic Parenchymal Metastasis in Patients with Primary Epithelial Ovarian Cancer Gynecol. Oncol. 2009, 112, 28-34 10.1016/j.ygyno.2008.09.046
5. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial Drug Therapy for Cancer in the Post-Genomic Era Nat. Biotechnol. 2012, 30, 679-692 10.1038/nbt.2284
6. DeVita, V. T., Jr.; Young, R. C.; Canellos, G. P. Combination Versus Single Agent Chemotherapy: A Review of the Basis for Selection of Drug Treatment of Cancer Cancer 1975, 35, 98-110 10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B
7. Agarwal, R.; Kaye, S. B. Ovarian Cancer: Strategies for Overcoming Resistance to Chemotherapy Nat. Rev. Cancer 2003, 3, 502-516 10.1038/nrc1123
8. Ariga, H.; Takahashi-Niki, K.; Kato, I.; Maita, H.; Niki, T.; Iguchi-Ariga, S. M. Neuroprotective Function of DJ-1 in Parkinson's Disease Oxid. Med. Cell. Longevity 2013, 2013, 683920 10.1155/2013/683920
9. Cao, J.; Lou, S.; Ying, M.; Yang, B. Dj-1 as a Human Oncogene and Potential Therapeutic Target Biochem. Pharmacol. 2015, 93, 241-250 10.1016/j.bcp.2014.11.012
10. Davidson, B.; Hadar, R.; Schlossberg, A.; Sternlicht, T.; Slipicevic, A.; Skrede, M.; Risberg, B.; Florenes, V. A.; Kopolovic, J.; Reich, R. Expression and Clinical Role of DJ-1, a Negative Regulator of Pten, in Ovarian Carcinoma Hum. Pathol. 2008, 39, 87-95 10.1016/j.humpath.2007.05.014
11. Yuen, H. F.; Chan, Y. P.; Law, S.; Srivastava, G.; El-Tanani, M.; Mak, T. W.; Chan, K. W. DJ-1 Could Predict Worse Prognosis in Esophageal Squamous Cell Carcinoma Cancer Epidemiol., Biomarkers Prev. 2008, 17, 3593-3602 10.1158/1055-9965.EPI-08-0214
12. Zeng, H. Z.; Qu, Y. Q.; Zhang, W. J.; Xiu, B.; Deng, A. M.; Liang, A. B. Proteomic Analysis Identified DJ-1 as a Cisplatin Resistant Marker in Non-Small Cell Lung Cancer Int. J. Mol. Sci. 2011, 12, 3489-3499 10.3390/ijms12063489
13. Hlobilkova, A.; Knillova, J.; Bartek, J.; Lukas, J.; Kolar, Z. The Mechanism of Action of the Tumour Suppressor Gene PTEN Biomed. Pap. 2003, 147, 19-25 10.5507/bp.2003.003
14. Kim, R. H.; Peters, M.; Jang, Y.; Shi, W.; Pintilie, M.; Fletcher, G. C.; DeLuca, C.; Liepa, J.; Zhou, L.; Snow, B.; Binari, R. C.; Manoukian, A. S.; Bray, M. R.; Liu, F. F.; Tsao, M. S.; Mak, T. W. DJ-1, a Novel Regulator of the Tumor Suppressor PTEN Cancer Cell 2005, 7, 263-273 10.1016/j.ccr.2005.02.010
15. Fan, J.; Ren, H.; Jia, N.; Fei, E.; Zhou, T.; Jiang, P.; Wu, M.; Wang, G. DJ-1 Decreases Bax Expression through Repressing P53 Transcriptional Activity J. Biol. Chem. 2008, 283, 4022-4030 10.1074/jbc.M707176200
16. Liu, C.; Chen, Y.; Kochevar, I. E.; Jurkunas, U. V. Decreased DJ-1 Leads to Impaired Nrf2-Regulated Antioxidant Defense and Increased UV-A-Induced Apoptosis in Corneal Endothelial Cells Invest. Ophthalmol. Visual Sci. 2014, 55, 5551-5560 10.1167/iovs.14-14580
17. Zhou, W.; Freed, C. R. DJ-1 up-Regulates Glutathione Synthesis During Oxidative Stress and Inhibits A53t Alpha-Synuclein Toxicity J. Biol. Chem. 2005, 280, 43150-43158 10.1074/jbc.M507124200
18. Chen, Y.; Kang, M.; Lu, W.; Guo, Q.; Zhang, B.; Xie, Q.; Wu, Y. DJ-1, a Novel Biomarker and a Selected Target Gene for Overcoming Chemoresistance in Pancreatic Cancer J. Cancer Res. Clin. Oncol. 2012, 138, 1463-1474 10.1007/s00432-012-1205-3
19. Harries, M.; Gore, M. Part I: Chemotherapy for Epithelial Ovarian Cancer-Treatment at First Diagnosis Lancet Oncol. 2002, 3, 529-536 10.1016/S1470-2045(02)00846-X
20. Li, X.; Taratula, O.; Taratula, O.; Schumann, C.; Minko, T. LHRH-Targeted Drug Delivery Systems for Cancer Therapy. Mini-Rev. Med. Chem. 2016, 16, in press.
21. Schumann, C.; Taratula, O.; Khalimonchuk, O.; Palmer, A. L.; Cronk, L. M.; Jones, C. V.; Escalante, C. A. ROS-Induced Nanotherapeutic Approach for Ovarian Cancer Treatment Based on the Combinatorial Effect of Photodynamic Therapy and DJ-1 Gene Suppression Nanomedicine 2015, 11, 1961-1970 10.1016/j.nano.2015.07.005
22. Shah, V.; Taratula, O.; Garbuzenko, O. B.; Taratula, O. R.; Rodriguez-Rodriguez, L.; Minko, T. Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of Sirna and Anticancer Drug Clin. Cancer Res. 2013, 19, 6193-6204 10.1158/1078-0432.CCR-13-1536
23. Taratula, O.; Garbuzenko, O. B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V. P.; He, H. X.; Minko, T. Surface-Engineered Targeted PPI Dendrimer for Efficient Intracellular and Intratumoral siRNA Delivery J. Controlled Release 2009, 140, 284-293 10.1016/j.jconrel.2009.06.019
24. Taratula, O.; Garbuzenko, O.; Savla, R.; Wang, Y. A.; He, H.; Minko, T. Multifunctional Nanomedicine Platform for Cancer Specific Delivery of Sirna by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes Curr. Drug Delivery 2011, 8, 59-69 10.2174/156720111793663642
25. Taratula, O.; Kuzmov, A.; Shah, M.; Garbuzenko, O. B.; Minko, T. Nanostructured Lipid Carriers as Multifunctional Nanomedicine Platform for Pulmonary Co-Delivery of Anticancer Drugs and siRNA J. Controlled Release 2013, 171, 349-357 10.1016/j.jconrel.2013.04.018
26. Taratula, O.; Savla, R.; He, H.; Minko, T. Poly(propyleneimine) Dendrimers as Potential siRNA Delivery Nanocarrier: From Structure to Function Int. J. Nanotechnol. 2011, 8, 36-52 10.1504/IJNT.2011.037169
27. Taratula, O.; Schumann, C.; Naleway, M. A.; Pang, A. J.; Chon, K. J. A Multifunctional Theranostic Platform Based on Phthalocyanine-Loaded Dendrimer for Image-Guided Drug Delivery and Photodynamic Therapy Mol. Pharmaceutics 2013, 10, 3946-3958 10.1021/mp400397t
28. Taratula, O.; Doddapaneni, B. S.; Schumann, C.; Li, X.; Bracha, S.; Milovancev, M.; Alani, A.; Taratula, O. Naphthalocyanine-Based Biodegradable Polymeric Nanoparticles for Image-Guided Combinatorial Phototherapy Chem. Mater. 2015, 27, 6155-6165 10.1021/acs.chemmater.5b03128
29. Taratula, O.; Patel, M.; Schumann, C.; Naleway, M. A.; Pang, A. J.; He, H. Phthalocyanine-Loaded Graphene Nanoplatform for Imaging-Guided Combinatorial Phototherapy Int. J. Nanomed. 2015, 10, 2347-2362 10.2147/IJN.S81097
30. Schumann, C.; Taratula, O.; Khalimonchuk, O.; Palmer, A. L.; Cronk, L. M.; Jones, C. V.; Escalante, C. A.; Taratula, O. ROS-Induced Nanotherapeutic Approach for Ovarian Cancer Treatment Based on the Combinatorial Effect of Photodynamic Therapy and DJ-1 Gene Suppression Nanomedicine 2015, 11, 1961-1970 10.1016/j.nano.2015.07.005
31. Dani, R. K.; Schumann, C.; Taratula, O. Temperature-Tunable Iron Oxide Nanoparticles for Remote-Controlled Drug Release AAPS PharmSciTech 2014, 15, 963-972 10.1208/s12249-014-0131-x
32. Arif, T.; Vasilkovsky, L.; Refaely, Y.; Konson, A.; Shoshan-Barmatz, V. Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth in Vivo Mol. Ther. - Nucleic Acids 2014, 3, e159 10.1038/mtna.2014.9
33. Beaufort, C. M.; Helmijr, J. C.; Piskorz, A. M.; Hoogstraat, M.; Ruigrok-Ritstier, K.; Besselink, N.; Murtaza, M.; van IJcken, W. F.; Heine, A. A.; Smid, M.; Koudijs, M. J.; Brenton, J. D.; Berns, E. M.; Helleman, J. Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of in Vitro Morphological Subtypes PLoS One 2014, 9, e103988 10.1371/journal.pone.0103988
34. Benard, J.; Da Silva, J.; De Blois, M. C.; Boyer, P.; Duvillard, P.; Chiric, E.; Riou, G. Characterization of a Human Ovarian Adenocarcinoma Line, IGROV1, in Tissue Culture and in Nude Mice Cancer Res. 1985, 45, 4970-4979
35. Borna, H.; Imani, S.; Iman, M.; Azimzadeh Jamalkandi, S. Therapeutic Face of RNAi: In Vivo Challenges Expert Opin. Biol. Ther. 2015, 15, 269-285 10.1517/14712598.2015.983070
36. Arencibia, J. M.; Bajo, A. M.; Schally, A. V.; Krupa, M.; Chatzistamou, I.; Nagy, A. Effective Treatment of Experimental ES-2 Human Ovarian Cancers with a Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Anti-Cancer Drugs 2002, 13, 949-956 10.1097/00001813-200210000-00007
37. Volker, P.; Grundker, C.; Schmidt, O.; Schulz, K. D.; Emons, G. Expression of Receptors for Luteinizing Hormone-Releasing Hormone in Human Ovarian and Endometrial Cancers: Frequency, Autoregulation, and Correlation with Direct Antiproliferative Activity of Luteinizing Hormone-Releasing Hormone Analogues Am. J. Obstet. Gynecol. 2002, 186, 171-179 10.1067/mob.2002.119633
38. Khan, A. R.; Magnusson, J. P.; Watson, S.; Grabowska, A. M.; Wilkinson, R. W.; Alexander, C.; Pritchard, D. Camptothecin Prodrug Block Copolymer Micelles with High Drug Loading and Target Specificity Polym. Chem. 2014, 5, 5320-5329 10.1039/C4PY00369A
39. Dharap, S. S.; Qiu, B.; Williams, G. C.; Sinko, P.; Stein, S.; Minko, T. Molecular Targeting of Drug Delivery Systems to Ovarian Cancer by BH3 and LHRH Peptides J. Controlled Release 2003, 91, 61-73 10.1016/S0168-3659(03)00209-8
40. Ho, M. N.; Delgado, C. H.; Owens, G. A.; Steller, M. A. Insulin-Like Growth Factor-II Participates in the Biphasic Effect of a Gonadotropin-Releasing Hormone Agonist on Ovarian Cancer Cell Growth Fertil. Steril. 1997, 67, 870-876 10.1016/S0015-0282(97)81399-4
41. Keller, G.; Schally, A. V.; Gaiser, T.; Nagy, A.; Baker, B.; Halmos, G.; Engel, J. B. Receptors for Luteinizing Hormone Releasing Hormone (LHRH) Expressed in Human Non-Hodgkin's Lymphomas Can Be Targeted for Therapy with the Cytotoxic LHRH Analogue AN-207 Eur. J. Cancer 2005, 41, 2196-2202 10.1016/j.ejca.2005.06.018
42. Shah, V.; Taratula, O.; Garbuzenko, O. B.; Taratula, O. R.; Rodriguez-Rodriguez, L.; Minko, T. Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug Clin. Cancer Res. 2013, 19, 6193-6204 10.1158/1078-0432.CCR-13-1536
43. Taira, T.; Saito, Y.; Niki, T.; Iguchi-Ariga, S. M.; Takahashi, K.; Ariga, H. DJ-1 Has a Role in Antioxidative Stress to Prevent Cell Death EMBO Rep. 2004, 5, 213-218 10.1038/sj.embor.7400074
44. Tabernero, J.; Shapiro, G. I.; LoRusso, P. M.; Cervantes, A.; Schwartz, G. K.; Weiss, G. J.; Paz-Ares, L.; Cho, D. C.; Infante, J. R.; Alsina, M.; Gounder, M. M.; Falzone, R.; Harrop, J.; White, A. C.; Toudjarska, I.; Bumcrot, D.; Meyers, R. E.; Hinkle, G.; Svrzikapa, N.; Hutabarat, R. M.; Clausen, V. A.; Cehelsky, J.; Nochur, S. V.; Gamba-Vitalo, C.; Vaishnaw, A. K.; Sah, D. W.; Gollob, J. A.; Burris, H. A., 3rd First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement Cancer Discovery 2013, 3, 406-417 10.1158/2159-8290.CD-12-0429
45. Rannikko, E. H.; Vesterager, L. B.; Shaik, J. H.; Weber, S. S.; Cornejo Castro, E. M.; Fog, K.; Jensen, P. H.; Kahle, P. J. Loss of DJ-1 Protein Stability and Cytoprotective Function by Parkinson's Disease-Associated Proline-158 Deletion J. Neurochem. 2013, 125, 314-327 10.1111/jnc.12126
46. Zhang, G. Q.; He, C.; Tao, L.; Liu, F. Role of DJ-1 siRNA in Reverse Sensitivity of Breast Cancer Cells to Chemotherapy and Its Possible Mechanism Int. J. Clin. Exp. Pathol. 2015, 8, 6944-6951
47. He, X.; Zheng, Z.; Li, J.; Ben, Q.; Liu, J.; Zhang, J.; Ji, J.; Yu, B.; Chen, X.; Su, L.; Zhou, L.; Liu, B.; Yuan, Y. DJ-1 Promotes Invasion and Metastasis of Pancreatic Cancer Cells by Activating SRC/ERK/uPA Carcinogenesis 2012, 33, 555-562 10.1093/carcin/bgs002
48. Pei, X. J.; Wu, T. T.; Li, B.; Tian, X. Y.; Li, Z.; Yang, Q. X. Increased Expression of Macrophage Migration Inhibitory Factor and DJ-1 Contribute to Cell Invasion and Metastasis of Nasopharyngeal Carcinoma Int. J. Med. Sci. 2014, 11, 106-115 10.7150/ijms.7264
49. Fang, M.; Zhong, X.; Du, B.; Lin, C.; Luo, F.; Tang, L.; Chen, J. Role of DJ-1 Induced PTEN Downregulation in Migration and Invasion of Human Glioma Cells Aizheng 2010, 29, 988-994 10.5732/cjc.010.10307
50. Dasari, S.; Tchounwou, P. B. Cisplatin in Cancer Therapy: Molecular Mechanisms of Action Eur. J. Pharmacol. 2014, 740, 364-378 10.1016/j.ejphar.2014.07.025
51. Kim, Y. C.; Kitaura, H.; Taira, T.; Iguchi-Ariga, S. M. M.; Ariga, H. Oxidation of DJ-1-Dependent Cell Transformation through Direct Binding of DJ-1 to PTEN Int. J. Oncol. 2009, 35, 1331-1341 10.3892/ijo-00000451
52. Wang, B.; Qin, H.; Wang, Y.; Chen, W.; Luo, J.; Zhu, X.; Wen, W.; Lei, W. Effect of DJ-1 Overexpression on the Proliferation, Apoptosis, Invasion and Migration of Laryngeal Squamous Cell Carcinoma SNU-46 Cells through PI3K/AKT/mTOR Oncol. Rep. 2014, 32, 1108-1116 10.3892/or.2014.3286
53. Vasseur, S.; Afzal, S.; Tardivel-Lacombe, J.; Park, D. S.; Iovanna, J. L.; Mak, T. W. DJ-1/Park7 Is an Important Mediator of Hypoxia-Induced Cellular Responses Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 1111-1116 10.1073/pnas.0812745106
54. Chiang, M. F.; Chou, P. Y.; Wang, W. J.; Sze, C. I.; Chang, N. S. Tumor Suppressor WWOX and P53 Alterations and Drug Resistance in Glioblastomas Front. Oncol. 2013, 3, 43 10.3389/fonc.2013.00043
55. Kato, I.; Maita, H.; Takahashi-Niki, K.; Saito, Y.; Noguchi, N.; Iguchi-Ariga, S. M.; Ariga, H. Oxidized DJ-1 Inhibits P53 by Sequestering p53 from Promoters in a DNA-Binding Affinity-Dependent Manner Mol. Cell. Biol. 2013, 33, 340-359 10.1128/MCB.01350-12
56. Astanehe, A.; Arenillas, D.; Wasserman, W. W.; Leung, P. C.; Dunn, S. E.; Davies, B. R.; Mills, G. B.; Auersperg, N. Mechanisms Underlying P53 Regulation of PIK3CA Transcription in Ovarian Surface Epithelium and in Ovarian Cancer J. Cell Sci. 2008, 121, 664-674 10.1242/jcs.013029
57. Li, T. M.; Chen, G. W.; Su, C. C.; Lin, J. G.; Yeh, C. C.; Cheng, K. C.; Chung, J. G. Ellagic Acid Induced p53/p21 Expression, G1 Arrest and Apoptosis in Human Bladder Cancer T24 Cells Anticancer Res. 2005, 25, 971-979
58. Choudhuri, T.; Pal, S.; Agwarwal, M. L.; Das, T.; Sa, G. Curcumin Induces Apoptosis in Human Breast Cancer Cells through p53-Dependent Bax Induction FEBS Lett. 2002, 512, 334-340 10.1016/S0014-5793(02)02292-5
59. Liou, G. Y.; Storz, P. Reactive Oxygen Species in Cancer Free Radical Res. 2010, 44, 479-496 10.3109/10715761003667554
60. Takemoto, H.; Ishii, A.; Miyata, K.; Nakanishi, M.; Oba, M.; Ishii, T.; Yamasaki, Y.; Nishiyama, N.; Kataoka, K. Polyion Complex Stability and Gene Silencing Efficiency with a siRNA-Grafted Polymer Delivery System Biomaterials 2010, 31, 8097-8105 10.1016/j.biomaterials.2010.07.015
61. Lev, N.; Ickowicz, D.; Melamed, E.; Offen, D. Oxidative Insults Induce DJ-1 Upregulation and Redistribution: Implications for Neuroprotection NeuroToxicology 2008, 29, 397-405 10.1016/j.neuro.2008.01.007
62. Godwin, A. K.; Meister, A.; O'Dwyer, P. J.; Huang, C. S.; Hamilton, T. C.; Anderson, M. E. High Resistance to Cisplatin in Human Ovarian Cancer Cell Lines Is Associated with Marked Increase of Glutathione Synthesis Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 3070-3074 10.1073/pnas.89.7.3070
63. Clements, C. M.; McNally, R. S.; Conti, B. J.; Mak, T. W.; Ting, J. P. DJ-1, a Cancer- and Parkinson's Disease-Associated Protein, Stabilizes the Antioxidant Transcriptional Master Regulator Nrf2 Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 15091-15096 10.1073/pnas.0607260103
64. Malhotra, D.; Thimmulappa, R.; Navas-Acien, A.; Sandford, A.; Elliott, M.; Singh, A.; Chen, L.; Zhuang, X.; Hogg, J.; Pare, P.; Tuder, R. M.; Biswal, S. Expression of Concern: Decline in Nrf2-Regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, DJ-1 Am. J. Respir. Crit. Care Med. 2008, 178, 592-604 10.1164/rccm.200803-380OC
65. Wilson, M. A. The Role of Cysteine Oxidation in DJ-1 Function and Dysfunction Antioxid. Redox Signaling 2011, 15, 111-122 10.1089/ars.2010.3481
66. Harvey, C. J.; Thimmulappa, R. K.; Singh, A.; Blake, D. J.; Ling, G.; Wakabayashi, N.; Fujii, J.; Myers, A.; Biswal, S. Nrf2-Regulated Glutathione Recycling Independent of Biosynthesis Is Critical for Cell Survival During Oxidative Stress Free Radical Biol. Med. 2009, 46, 443-453 10.1016/j.freeradbiomed.2008.10.040
67. Ma, Q. Role of Nrf2 in Oxidative Stress and Toxicity Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401-426 10.1146/annurev-pharmtox-011112-140320
68. Kinumi, T.; Kimata, J.; Taira, T.; Ariga, H.; Niki, E. Cysteine-106 of DJ-1 Is the Most Sensitive Cysteine Residue to Hydrogen Peroxide-Mediated Oxidation in Vivo in Human Umbilical Vein Endothelial Cells Biochem. Biophys. Res. Commun. 2004, 317, 722-728 10.1016/j.bbrc.2004.03.110
69. Kim, H. J.; Lee, J. H.; Kim, S. J.; Oh, G. S.; Moon, H. D.; Kwon, K. B.; Park, C.; Park, B. H.; Lee, H. K.; Chung, S. Y.; Park, R.; So, H. S. Roles of NADPH Oxidases in Cisplatin-Induced Reactive Oxygen Species Generation and Ototoxicity J. Neurosci. 2010, 30, 3933-3946 10.1523/JNEUROSCI.6054-09.2010
70. Marullo, R.; Werner, E.; Degtyareva, N.; Moore, B.; Altavilla, G.; Ramalingam, S. S.; Doetsch, P. W. Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions PLoS One 2013, 8, e81162 10.1371/journal.pone.0081162